.png)
Business Description
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer and liver cancer. Provectus investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for psoriasis. In addition, Provectus has begun a Phase 3 trial as a therapy for metastatic melanoma. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
The red synthetic dye Rose Bengal is shown in a bottle at Provectus Pharmaceuticals, Inc.
CURRENT PVCT PIPELINE (as of May 23, 2017)
--------------------------------------------------------------
Charts and Technical:
PVCT 6 months chart:
http://stockcharts.com/h-sc/ui?s=PVCT&p=D&yr=0&mn=6&dy=0&id=p03754661229
Technical analysis:
http://www.stockta.com/cgi-bin/analysis.pl?symb=PVCT&num1=7&cobrand=&mode=stock
PVCT News and Analysis:
PVCT News Blog with the latest news and analysis:
http://provectuspharmaceuticalsinc.blogspot.ca/p/news.html
CONNECTING THE DOTS - CURRENT NEWS PAGE
http://provectuspharmaceuticalsinc.blogspot.ca/p/current-news_22.html
CONNECTING THE DOTS - BLOG PAGE
http://provectuspharmaceuticalsinc.blogspot.ca/
PVCT News at OTC
http://www.otcmarkets.com/stock/PVCT/news
CLINICAL TRIALS Updates and Info:
FOR PV-10 CLINICAL TRIALS:
https://clinicaltrials.gov/ct2/results?term=PV-10&Search=Search
FOR PH-10 CLINICAL TRIALS:
https://clinicaltrials.gov/ct2/results?term=PH-10&Search=Search
PVCT insiders transactions:
http://www.secform4.com/insider/showhistory.php?symbol=pvct
For Clinical Trials and Compassionate Use Programs, Investor Information including SEC filing and Corporate Presentations, Press and Media Releases, and Contact information:
http://www.pvct.com/index.html
PVCT on YouTube...
http://www.youtube.com/watch?v=nuYpvcnAq4c
------------------------------------------------------------
Contact Info:
Telephone: (866) 594-5999
info@pvct.com
scott@pvct.com
Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA
--------------------------------------------------------------
PVCT Share Structure
Market Value: $18,517,732 a/o May 04, 2017
Authorized Shares: 1,000,000,000 a/o Apr 30, 2017
Outstanding Shares: 370,354,643 a/o Apr 30, 2017
-Restricted: N/A
-Unrestricted: N/A
Held at DTC: N/A
Float: 75,807,312 a/o Jun 30, 2016
Par Value: 0.001
Shareholders of Record: 972 a/o Mar 31, 2017
Short Selling Data